Abivax (ABVX) Competitors

BeOne Medicines currently has a consensus target price of $390.58, indicating a potential upside of 32.00%. Abivax has a consensus target price of $137.15, indicating a potential upside of 11.69%. Given BeOne Medicines' higher probable upside, analysts clearly believe BeOne Medicines is more favorable than Abivax.

BeOne Medicines has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500. Comparatively, Abivax has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500.

BeOne Medicines has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

48.6% of BeOne Medicines shares are owned by institutional investors. Comparatively, 47.9% of Abivax shares are owned by institutional investors. 6.6% of BeOne Medicines shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Abivax had 3 more articles in the media than BeOne Medicines. MarketBeat recorded 7 mentions for Abivax and 4 mentions for BeOne Medicines. Abivax's average media sentiment score of 1.45 beat BeOne Medicines' score of 1.28 indicating that Abivax is being referred to more favorably in the news media.

BeOne Medicines has a net margin of 5.37% compared to Abivax's net margin of 0.00%. BeOne Medicines' return on equity of 10.70% beat Abivax's return on equity.

Abivax currently has a consensus target price of $137.15, suggesting a potential upside of 11.69%. Insmed has a consensus target price of $213.23, suggesting a potential upside of 52.45%. Given Insmed's stronger consensus rating and higher possible upside, analysts clearly believe Insmed is more favorable than Abivax.

Abivax has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500. Comparatively, Insmed has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500.

Abivax has higher earnings, but lower revenue than Insmed. Abivax is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

47.9% of Abivax shares are owned by institutional investors. 2.1% of Insmed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Insmed had 6 more articles in the media than Abivax. MarketBeat recorded 13 mentions for Insmed and 7 mentions for Abivax. Abivax's average media sentiment score of 1.45 beat Insmed's score of 1.04 indicating that Abivax is being referred to more favorably in the media.

Abivax has a net margin of 0.00% compared to Insmed's net margin of -210.54%. Abivax's return on equity of -146.43% beat Insmed's return on equity.

Abivax has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500. Comparatively, Revolution Medicines has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500.

Revolution Medicines is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks.

Abivax currently has a consensus target price of $137.15, suggesting a potential upside of 11.69%. Revolution Medicines has a consensus target price of $78.94, suggesting a potential downside of 46.26%. Given Abivax's higher possible upside, equities analysts clearly believe Abivax is more favorable than Revolution Medicines.

In the previous week, Revolution Medicines had 6 more articles in the media than Abivax. MarketBeat recorded 13 mentions for Revolution Medicines and 7 mentions for Abivax. Abivax's average media sentiment score of 1.45 beat Revolution Medicines' score of 0.92 indicating that Abivax is being referred to more favorably in the media.

Revolution Medicines' return on equity of -63.10% beat Abivax's return on equity.

47.9% of Abivax shares are owned by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are owned by institutional investors. 8.2% of Revolution Medicines shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Abivax has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500. Comparatively, BioNTech has a beta of 1.36, indicating that its stock price is 36% more volatile than the S&P 500.

Abivax has higher earnings, but lower revenue than BioNTech. Abivax is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Abivax currently has a consensus target price of $137.15, suggesting a potential upside of 11.69%. BioNTech has a consensus target price of $133.13, suggesting a potential upside of 38.76%. Given BioNTech's higher possible upside, analysts plainly believe BioNTech is more favorable than Abivax.

In the previous week, BioNTech had 5 more articles in the media than Abivax. MarketBeat recorded 12 mentions for BioNTech and 7 mentions for Abivax. Abivax's average media sentiment score of 1.45 beat BioNTech's score of 1.20 indicating that Abivax is being referred to more favorably in the media.

Abivax has a net margin of 0.00% compared to BioNTech's net margin of -38.09%. BioNTech's return on equity of -4.76% beat Abivax's return on equity.

47.9% of Abivax shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 19.2% of BioNTech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.